Streetbeat News

Analyst Ratings

LXRX

Over the past three months, 5 analysts have evaluated Lexicon Pharmaceuticals (NASDAQ:LXRX), with all ratings being bullish. The average 12-month price target remains at $10.00. Key analyst Joseph Pantginis from HC Wainwright & Co. consistently maintains a 'Buy' rating with a $10.00 price target. Lexicon Pharmaceuticals has shown significant revenue growth and maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

August 02, 2024 | 6:09 pm

BFAM

Deutsche Bank analyst Faiza Alwy maintains a Hold rating on Bright Horizons Family (NYSE:BFAM) and raises the price target from $114 to $140.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 6:08 pm

DASH

JMP Securities has maintained a Market Outperform rating on DoorDash and raised its price target from $140 to $145.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 6:08 pm

VCEL

Analysts have provided a range of ratings for Vericel (NASDAQ:VCEL) over the past quarter, with all five analysts giving a bullish rating. The average 12-month price target has increased to $56.4, reflecting a 2.55% rise from the previous target. Vericel has shown strong revenue growth and effective asset utilization, but faces challenges in ROE and net margin.

Portfolio Pulse from Benzinga Insights

August 02, 2024 | 6:08 pm

MSTR

RIOT

Riot Platforms, Inc. (NASDAQ:RIOT) shares are down amid a decline in Bitcoin prices. Riot's stock is trading below its 50-day moving average and near the lower end of its 52-week range. The company reported worse-than-expected earnings for Q2 2024, leading to price target adjustments from several analysts. Other crypto-linked stocks like MicroStrategy Inc. (NASDAQ:MSTR) are also trading lower.

Portfolio Pulse from Dylan Berman

August 02, 2024 | 6:07 pm

BHC

Bausch Health Companies (NYSE:BHC) reported a second-quarter 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenues were $2.403 billion, up 11% year-over-year, beating the consensus of $2.339 billion. Despite positive revenue growth, Piper Sandler downgraded Bausch to Underweight from Neutral, citing solvency concerns with $9.4 billion in debt maturing in 2027/2028 and Xifaxan losing exclusivity by January 2028. BHC stock is down 6.80% at $5.69.

Portfolio Pulse from Vandana Singh

August 02, 2024 | 6:06 pm

WK

Northland Capital Markets has maintained an Outperform rating on Workiva (NYSE:WK) but lowered the price target from $106 to $95.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 6:05 pm

GOOS

Wells Fargo analyst Ike Boruchow maintains an Equal-Weight rating on Canada Goose Holdings but lowers the price target from C$19 to C$16.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 6:04 pm

CLFD

Northland Capital Markets has maintained an Outperform rating on Clearfield (NASDAQ:CLFD) and raised the price target from $40 to $45.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 6:03 pm

SEM

Over the past three months, four analysts have evaluated Select Medical Holdings (NYSE:SEM), with the majority being bullish. The average 12-month price target has increased to $44.5, reflecting a 7.88% rise. Analysts from Benchmark and RBC Capital have raised their price targets, indicating positive sentiment. Despite strong financial metrics like net margin and ROE, the company faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

August 02, 2024 | 6:02 pm